肝动脉灌注奥沙利铂联合系统化疗及靶向治疗不可切除结直肠癌肝转移
本研究为单中心连续病例分析,纳入2005至2016年89例不可切除结直肠癌肝转移患者,接受至少一周期肝动脉灌注奥沙利铂联合系统化疗及靶向治疗。结果显示3/4级毒性包括中性粒细胞减少40%、灌注相关腹痛43%和神经毒性12%,意向治疗客观缓解率42%,27%患者获得完全切除或消融,中位总生存20个月、无进展生存9个月。
要点
- 肝动脉灌注奥沙利铂联合系统化疗及靶向治疗可行且安全
- 意向治疗客观缓解率42%,27%患者转为可完全切除或消融
- 中位总生存20个月,中位无进展生存9个月
核心结论
- 在系统化疗基础上联合靶向治疗与肝动脉灌注奥沙利铂可行、安全,并显示出有前景的抗肿瘤活性,即使系统化疗失败后仍可考虑。
研究设计与样本
- 单中心回顾性连续病例分析,纳入2005至2016年接受至少一周期肝动脉灌注奥沙利铂联合系统化疗及靶向治疗的不可切除结直肠癌肝转移患者89例。
- 患者中位年龄55岁(范围26-76岁),既往接受中位1线系统化疗(范围0-5线),78%既往用过奥沙利铂。
- 肝动脉灌注奥沙利铂中位9周期(范围1-28周期),系统化疗为LV5FU2(63%)或FOLFIRI(36%),靶向治疗为抗EGFR(30%)或贝伐珠单抗(70%)。
主要发现
- 3/4级毒性包括中性粒细胞减少40%、肝动脉灌注相关腹痛43%、神经毒性12%。
- 意向治疗客观缓解率42%,45%患者疾病稳定,27%患者实现结直肠癌肝转移完全切除或消融。
- 中位随访72个月,中位总生存20个月,中位无进展生存9个月。
临床怎么用
- 对不可切除结直肠癌肝转移患者,可考虑肝动脉灌注奥沙利铂联合系统化疗及靶向治疗作为转化或姑息治疗策略。
- 治疗期间需关注中性粒细胞减少、灌注相关腹痛和神经毒性等3/4级不良反应。
局限性
- 单中心回顾性研究,样本量有限,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatic arterial infusion (HAI) combined with systemic chemotherapy has shown promising results in patients with unresectable colorectal liver metastases (CRLM), even after failure to systemic therapy. Addition of systemic targeted therapies has been investigated with controversial results regarding tolerance, especially with HAI-floruxidine when combined with systemic bevacizumab. Our study aimed to analyse feasibility, safety and efficacy of HAI-oxaliplatin plus systemic chemotherapy and targeted therapies. METHODS: Between 2005 and 2016, single-centre consecutive patients with unresectable CRLM who received at least one cycle of HAI-oxaliplatin plus systemic chemotherapy and targeted therapies (cetuximab/panitumumab or bevacizumab) were analysed. RESULTS: A total of 89 patients (median age 55 years (range, 26-76 years) who previously received a median number of one systemic chemotherapy regimen (range, 0-5) including oxaliplatin in 78% of cases were included. Median number of HAI-oxaliplatin cycles was 9 (range, 1-28) combined with systemic chemotherapy and targeted therapies (LV5FU2 [63%], FOLFIRI [36%]) plus anti-EGFR (30%), or bevacizumab (70%). Grade 3/4 toxicities included neutropenia (40%), HAI-related abdominal pain (43%) and neurotoxicity (12%). The intent-to-treat objective response rate was 42%, and 45% had stable disease, allowing complete CRLM resection/ablation in 27% of patients. After a median follow-up of 72 months, median overall and progression-free survival was 20 and 9 months, respectively. CONCLUSION: Addition of targeted therapy to systemic chemotherapy combined with HAI-oxaliplatin is feasible, safe and shows promising activity, even after systemic chemotherapy failure.
引用
- Boilève A, De Cuyper A, Larive A, et al. Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases. Eur J Cancer. 2020. PMID: 32871526. doi:10.1016/j.ejca.2020.07.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。